Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy

被引：10
作者：
Goldhagen B.E. [1 ]
Goldhardt R. [1 ]
机构：
[1] Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th Street, Miami, 33136, FL
来源：
Current Ophthalmology Reports | 2017年 / 5卷 / 2期
基金：
美国国家卫生研究院;
关键词：
Central serous chorioretinopathy; Central serous retinopathy; CSCR; CSR; Micropulse; Photodynamic therapy; Spironolactone; Subthreshold laser;
D O I：
10.1007/s40135-017-0133-4
中图分类号：
学科分类号：
摘要：
Purpose of Review: The goal of this paper is to provide a comprehensive review of the management options for central serous chorioretinopathy (CSCR). Recent Findings: The majority of cases of acute CSCR may be managed with observation and cessation of corticosteroids, if possible, as well as lifestyle modifications including stress reduction and control of hypertension. The management of chronic disease is more challenging and may include either medication or laser-based treatment. Summary: Management of CSCR necessitates an individualized and selective treatment approach. There is overall poor evidence for the use of systemic and intravitreal medications. From this class of treatments, mineralocorticoid receptor antagonists appear to have the greatest potential. Although conventional thermal photocoagulation may be used in select cases, the most promising treatment options at this time for chronic CSCR are photodynamic therapy, either half-dose or half-fluence, and non-damaging (subthreshold) retinal laser therapy. © 2017, Springer Science + Business Media New York.
引用
收藏
页码：141 / 148
页数：7
相关论文
共 72 条
[1]  
Agarwal A., Diseases causing exudative and hemorrhagic detachment of the choroid, retina and retinal pigment epithelium. Gass' atlas of macular diseases, pp. 66-91, (2012)
[2]  
Kitzmann A.S., Pulido J.S., Diehl N.N., Hodge D.O., Burke J.P., The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002, Ophthalmology, 115, 1, pp. 169-173, (2008)
[3]  
Haimovici R., Koh S., Gagnon D.R., Lehrfeld T., Wellik S., Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study, Ophthalmology, 111, 2, pp. 244-249, (2004)
[4]  
Tittl M.K., Spaide R.F., Wong D., Et al., Systemic findings associated with central serous chorioretinopathy, Am J Ophthalmol, 128, 1, pp. 63-68, (1999)
[5]  
Yannuzzi L.A., Type A behavior and central serous chorioretinopathy, Trans Am Ophthalmol Soc, 84, pp. 799-845, (1986)
[6]  
Spaide R.F., Campeas L., Haas A., Et al., Central serous chorioretinopathy in younger and older adults, Ophthalmology, 103, 12, pp. 2070-2079, (1996)
[7]  
Brodie F.L., Charlson E.S., Aleman T.S., Et al., Obstructive sleep apnea and central serous chorioretinopathy, Retina, 35, 2, pp. 238-243, (2015)
[8]  
How A.C., Koh A.H., Angiographic characteristics of acute central serous chorioretinopathy in an Asian population, Ann Acad Med Singap, 35, 2, pp. 77-79, (2006)
[9]  
Tsai D.C., Chen S.J., Huang C.C., Et al., Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001–2006: a population-based study, PLoS One, 8, 6, (2013)
[10]  
Desai U.R., Alhalel A.A., Campen T.J., Schiffman R.M., Edwards P.A., Jacobsen G.R., Central serous chorioretinopathy in African Americans, J Natl Med Assoc, 95, 7, pp. 553-559, (2003)
12345678